Description: NervGen Pharma Corp., a regenerative medicine company, engages in the discovery, development, and commercialization of therapeutics for the treatment of nerve damage, including spinal cord injuries and peripheral nerve injuries. Its lead product candidate is the NVG-291 that is in clinical studies for the treatment of spinal cord injuries (SCI). It has a licensing agreement with Case Western Reserve University in Cleveland, Ohio to research, develop, and commercialize a patented technology with therapeutic potential for SCI and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.
Home Page: www.nervgen.com
2955 Virtual Way
Vancouver,
BC
V5M 4X6
Canada
Phone:
778 731 1711
Officers
| Name | Title |
|---|---|
| Mr. William Joseph Radvak BASc | Co-Founder, Interim CEO & Exec. Chairman |
| Dr. Harold Martin Punnett D.M.D. | Co-Founder & Independent Director |
| Mr. William J. Adams C.A., CPA, CA, CPA | CFO & Corp. Sec. |
| Dr. Daniel D. Mikol M.D., Ph.D. | Chief Medical Officer |
| Dr. Adam H. Rogers M.D. | Interim Pres & Director |
| Mr. Brian McAlister | Co-Founder & Advisor |
Exchange: OTCQX
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 5.1262 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |